Drug Information

 




 Bezafibrate

  













  

Pharmacokinetics

Bezafibrate is readily
absorbed from the gastrointestinal tract. Plasma protein binding is
about 95%. The plasma elimination half-life is about 2 hours. Most of a
dose is excreted in the urine, about half as unchanged drug, the
remainder as metabolites including the glucuronide conjugate. A small
proportion of the dose appears in the faeces.

Top

     

Indication & Dosage

Oral :

ALL FORMS OF HYPERLIPOPROTEINAEMIA. HYPERLIPIDAEMIA SECONDARY TO
DIABETES, GOUT, CHRONIC RENAL FAILURE :

Adults: 200mg t.i.d. reduced to b.i.d as good response is
established. 

Children : Limited experience with 5-10mg/kg twice daily in children
4-15yrs old. Tablets should be   

swallowed whole after meals. 

Elderly : Dose reduction may be necessary. Bezafibrate therapy should form
part of total management of
hyperlipidaemia. 

Impaired renal function : Dose redution according to creatinine levels.

Top

   

Action

Bezafibrate causes significant reduction in plasma
triglycerides and VLDL and LDL cholesterol. HDL levels are increased. Main
mode of action is to increase the activity of lipoprotein lipase and
several other enzymes. Increases the effects of anticoagulants in patients
with hyperlipoproteinaemia.

Top 

   

Interactions



Anti-coagulants: Increase
efficacy of anti-coagulants requring dose of the latter to be reduced by
half.

Sulfonly ureas: Activity potentiated.

Top

Adverse Effect & Precaution



Abdominal pain, nausea,
diarrhoea, alopecia, skin rash, leukipenia, myalgia.

Pregnancy: Contraindicated.

Breast Feeding: Contraindicated.

Top

     

Brands available in
Market



 








 






Bezalip
TAB 200mg 10 Boehringer Mannheim
R-TAB 400mg  10 Boehringer Mannheim



Top  




 

                                                  





 

       


Drug Information
 


 Bezafibrate
  

  
Pharmacokinetics

Bezafibrate is readily absorbed from the gastrointestinal tract. Plasma protein binding is about 95%. The plasma elimination half-life is about 2 hours. Most of a dose is excreted in the urine, about half as unchanged drug, the remainder as metabolites including the glucuronide conjugate. A small proportion of the dose appears in the faeces.

Top
     

Indication & Dosage

Oral :
ALL FORMS OF HYPERLIPOPROTEINAEMIA. HYPERLIPIDAEMIA SECONDARY TO DIABETES, GOUT, CHRONIC RENAL FAILURE :
Adults: 200mg t.i.d. reduced to b.i.d as good response is established. 
Children : Limited experience with 5-10mg/kg twice daily in children 4-15yrs old. Tablets should be   
swallowed whole after meals. 
Elderly : Dose reduction may be necessary. Bezafibrate therapy should form part of total management of hyperlipidaemia. 
Impaired renal function : Dose redution according to creatinine levels.

Top
   

Action

Bezafibrate causes significant reduction in plasma triglycerides and VLDL and LDL cholesterol. HDL levels are increased. Main mode of action is to increase the activity of lipoprotein lipase and several other enzymes. Increases the effects of anticoagulants in patients with hyperlipoproteinaemia.

Top 
   

Interactions

Anti-coagulants: Increase efficacy of anti-coagulants requring dose of the latter to be reduced by half.
Sulfonly ureas: Activity potentiated.

Top

Adverse Effect & Precaution

Abdominal pain, nausea, diarrhoea, alopecia, skin rash, leukipenia, myalgia.
Pregnancy: Contraindicated.
Breast Feeding: Contraindicated.

Top
     

 

Bezalip

TAB

200mg

10

Boehringer Mannheim

R-TAB

400mg 

10

Boehringer Mannheim

Top  

 

                                                  

 

By |2022-07-20T16:44:51+00:00July 20, 2022|Uncategorized|Comments Off on Bezafibrate

About the Author: